



HOUSE HEALTH COMMITTEE

VOTING MEETING

Tuesday, June 2nd, 2026

10:00am

Room G-50, Irvis Office Building
Harrisburg, PA

1. Call to Order

2. Attendance

3. **HB2162 PN2805 (Borowski)**

An Act amending the act of December 14, 1992 (P.L.1116, No.145), adjusting licensure requirements for manufacturers and virtual manufacturers.

A-03371 (Borowski) Creates a conditional license for manufacturers pending FDA approval of a drug.

HB2341 PN3114 (Ortitay)

An Act amending the act of April 9, 1929 (P.L.343, No.176), known as The Fiscal Code, establishing the Health Care Facility Threat Assessment Grant Program.

A-03394 (Frankel) Broadens the grant program to include addressing security, modeled after the Non-Profit Security Grant program.

HB1365 PN1559 (Deloso)

An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes establishing the Medication-Induced Movement Disorders Screening Education Program.

HR475 PN3258 (Rivera)

A Resolution recognizing the month of September 2026 as "ITP Awareness Month" in Pennsylvania.

HR494 PN3306 (Young)

A Resolution designating June 15, 2026, as "Elora Joyce Khan Pediatric Brain Cancer Awareness Day" in Pennsylvania.

HR502 PN3311 (Malagari)

A Resolution recognizing the month of September 2026 as "Thyroid Cancer Awareness Month" in Pennsylvania.

HR514 PN3361 (Diamond)

A Resolution designating October 13, 2026, as "Metastatic Breast Cancer Awareness Day" in Pennsylvania.

HR518 PN3362 (Diamond)

A Resolution recognizing the month of November 2026 as "National Epilepsy Awareness Month" in Pennsylvania.

HR529 PN3419 (Rapp)

A Resolution designating the week of September 20 through 27, 2026, as "Idiopathic Pulmonary Fibrosis Research and Awareness Week" in Pennsylvania.

HR531 PN3431 (Delozier)

A Resolution designating the month of June 2026 as "Scoliosis Awareness Month" in Pennsylvania.

HR535 PN3441 (Rapp)

A Resolution designating the week of September 20 through 26, 2026, as "Surgical Technologist Week" in Pennsylvania.

HR538 PN3444 (Matzie)

A Resolution designating the month of November 2026 as "Pancreatic Cancer Awareness Month" in Pennsylvania.

HR541 PN3457 (M. Brown)

A Resolution recognizing the month of June 2026 as "Aphasia Awareness Month" in Pennsylvania.

HR542 PN3458 (Rapp)

A Resolution recognizing October 24, 2026, as "World Polio Day" in Pennsylvania.

4. Any other business that may come before the committee.
5. Adjournment

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HB2162 PN2805	Prepared By:	Erika Fricke
Committee:	Health		717-908-7023
Sponsor:	Borowski, Lisa	Executive Director:	Erika Fricke
Date:	5/22/2026		

A. Brief Concept

Removes the requirement that pharmaceutical companies have FDA approval of their product in order to obtain licensure as a manufacturer or virtual manufacturer under Pennsylvania law.

B. Committee Votes

n/a

C. Analysis of the Bill

HB2162 removes the requirement that pharmaceutical companies have FDA approval of their product in order to obtain licensure as a virtual manufacturer under Pennsylvania law.

The bill redefines "virtual manufacturer" to state that a company that does not have a drug or device approval and label code, must verify that they have submitted an application to the Food and Drug Administration for approval, or that they intend to submit an application for approval.

Regardless, the Department may not make FDA approval of a drug a condition of licensure as a prescription drug manufacturer or virtual manufacturer in Pennsylvania.

Effective Date:

60 days

D. Third Party Feedback

Bio-tech supports

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A

F. Key Points

State licensure for drug distribution is required by federal law for prescription drugs, though the federal regulations do not require FDA approval prior to licensure.

Businesses need to get 38 separate state licenses in order to sell prescription drugs across state lines and eight states, plus Pennsylvania, require FDA approval before licensure: Idaho, Utah, Texas, Alabama, Florida, North Carolina, New York and New Hampshire.

The licensure time in PA is quick -- 4-6 weeks post FDA approval -- but FDA approval delays start.

PA requires a \$100,000 bond prior to licensure, to limit bad actors/fly-by-night companies.

Requiring FDA approval of a drug delays the process of obtaining state licenses because the home license must be procured first, which means all other state licenses, including states that don't require FDA approval, must take place after FDA approval, thereby lengthening the licensure process.

DOH expressed concern about tracking drug distribution if an FDA code is not required.

G. Relevant Existing Laws

Federal regulations require a state licensure in order to sell prescription drugs across state lines.

[eCFR :: 21 CFR Part 205 -- Guidelines for State Licensing of Wholesale Prescription Drug Distributors](#)

State Law and Regulation

§ 205.4 Wholesale drug distributor licensing requirement.

Every wholesale distributor in a State who engages in wholesale distributions of prescription drugs in interstate commerce must be licensed by the State licensing authority in accordance with this part before engaging in wholesale distributions of prescription drugs in interstate commerce.

In Pennsylvania, [the Wholesale Prescription Drug Distributors License Act \(Act 145 of 1992\)](#) requires that a virtual manufacturer hold the drug or device approval label code, or be identified on the label code in order to receive a virtual manufacturer's license.

The existing application for a manufacturer's license notes that the manufacturer or wholesale distributor must have the FDA code prior to applying for licensure.

[COMMONWEALTH OF PENNSYLVANIA](#)

H. Messaging

Making PA Business Friendly

Pennsylvania is already known for rapidly providing manufacturer licenses for prescription drugs, allowing for a conditional license earlier allows companies to headquarter here.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 2162 Session of
2026

INTRODUCED BY BOROWSKI, FRIEL, KUTZ, VENKAT, MAYES, MERSKI,
PIELLI, HILL-EVANS, PROBST, GUZMAN, BURGOS, SANCHEZ, BRENNAN,
MADDEN, CEPEDA-FREYTIZ, GALLAGHER, BOYD AND INGLIS,
JANUARY 28, 2026

REFERRED TO COMMITTEE ON HEALTH, JANUARY 28, 2026

AN ACT

1 Amending the act of December 14, 1992 (P.L.1116, No.145),
2 entitled "An act providing minimum standards, terms and
3 conditions for the licensing of persons who engage in
4 wholesale distributions in interstate commerce of
5 prescription drugs; and making a repeal," further providing
6 for definitions and for license application.

7 The General Assembly of the Commonwealth of Pennsylvania
8 hereby enacts as follows:

9 Section 1. The definition of "virtual manufacturer" in
10 section 3 of the act of December 14, 1992 (P.L.1116, No.145),
11 known as the Wholesale Prescription Drug Distributors License
12 Act, added October 16, 2024 (P.L.988, No.101), is amended to
13 read:

14 Section 3. Definitions.

15 The following words and phrases when used in this act shall
16 have the meanings given to them in this section unless the
17 context clearly indicates otherwise:

18 * * *

19 "Virtual manufacturer." A person with a place of business

1 located in this Commonwealth in the business of manufacturing
2 and distributing a drug or medical device that:

3 (1) Holds the drug or device approval and label code or
4 is otherwise identified on the product label from the United
5 States Food and Drug Administration[.] or has submitted an
6 application to the United States Food and Drug Administration
7 for approval of the drug or device or intends to submit an
8 application for approval within 12 months.

9 (2) At no time takes physical possession of any drug or
10 device in this Commonwealth.

11 * * *

12 Section 2. Section 5(a) of the act is amended by adding
13 paragraphs to read:

14 Section 5. License application.

15 (a) Information on application.--An applicant for a license
16 shall provide the following information on a license application
17 form approved by the department:

18 * * *

19 (6.2) If the applicant is a manufacturer of a
20 prescription drug that has not been approved by the United
21 States Food and Drug Administration, a statement that the
22 applicant has submitted an application to the United States
23 Food and Drug Administration for approval of the prescription
24 drug or that the applicant intends to submit an application
25 for approval within 12 months. The department may not require
26 approval of a prescription drug by the United States Food and
27 Drug Administration as a condition of licensure under this
28 act.

29 (6.3) If the applicant is a virtual manufacturer of a
30 drug or medical device and does not hold the drug or device

1 approval and label code or is not otherwise identified on the
2 product label from the United States Food and Drug
3 Administration, a statement that the applicant has submitted
4 an application to the United States Food and Drug
5 Administration for approval of the drug or device or that the
6 applicant intends to submit an application for approval
7 within 12 months. The department may not require approval of
8 a drug or medical device by the United States Food and Drug
9 Administration as a condition of licensure under this act.

10 * * *

11 Section 3. This act shall take effect in 60 days.

LEGISLATIVE REFERENCE BUREAU

AMENDMENTS TO HOUSE BILL NO. 2162

Sponsor:

Printer's No. 2805

1 Amend Bill, page 1, lines 9 through 13, by striking out all
2 of said lines and inserting

3 Section 1. Section 3 of the act of December 14, 1992
4 (P.L.1116, No.145), known as the Wholesale Prescription Drug
5 Distributors License Act, is amended by adding a definition to
6 read:

7 Amend Bill, page 1, line 19; page 2, lines 1 through 10; by
8 striking out all of said lines on said pages and inserting

9 "Conditional license." A temporary license issued by the
10 department to a manufacturer or a virtual manufacturer for a
11 drug or medical device that has not yet received final approval
12 from the United States Food and Drug Administration.

13 Amend Bill, page 2, lines 12 through 30; page 3, lines 1
14 through 10; by striking out all of said lines on said pages and
15 inserting

16 Section 2. Section 5 of the act is amended by adding a
17 subsection to read:

18 Section 5. License application.

19 * * *

20 (a.2) Conditional license.--

21 (1) If the applicant is a manufacturer of a prescription
22 drug or a virtual manufacturer of a drug or medical device
23 that has not yet received approval from the United States
24 Food and Drug Administration, the department may issue a
25 conditional license if the applicant submits all of the
26 following:

27 (i) Documentation demonstrating that an application
28 for approval has been submitted to the United States Food
29 and Drug Administration, including, where applicable:

30 (A) a new drug application number;

31 (B) an abbreviated new drug application number;

32 (C) a biologics license application number;

33 (D) a unique device identification number; or

1 (E) other documentation acceptable to the
2 department demonstrating active review by the United
3 States Food and Drug Administration.

4 (ii) Documentation identifying any contract
5 manufacturing organization or licensed manufacturing
6 facility involved in the manufacture, packaging, labeling
7 or distribution of the drug or medical device.

8 (iii) Documentation demonstrating compliance with
9 applicable requirements of 21 U.S.C. Ch. 9 Subch. V Pt. H
10 (relating to pharmaceutical distribution supply chain).

11 (2) A conditional license issued under paragraph (1):

12 (i) shall expire one year after issuance unless
13 renewed by the department;

14 (ii) shall automatically expire upon denial,
15 withdrawal or refusal of the applicant's approval
16 application by the United States Food and Drug
17 Administration;

18 (iii) may not authorize commercial distribution of a
19 drug or device unless otherwise permitted under Federal
20 law; and

21 (iv) does not create a property interest in the
22 conditional license and may be suspended or revoked by
23 the department for failure to maintain compliance with
24 this act or applicable Federal law.

25 (3) An applicant issued a conditional license under
26 paragraph (1) shall notify the department within five
27 business days of:

28 (i) approval, denial, withdrawal or refusal of an
29 application by the United States Food and Drug
30 Administration; or

31 (ii) any material change to the applicant's
32 manufacturing or distribution arrangements.

33 (4) Issuance of a conditional license or a license under
34 this subsection may not be construed as approval, endorsement
35 or authorization of a drug or medical device by the
36 Commonwealth.

37 (5) The department may promulgate regulations and
38 develop monitoring, reporting and enforcement procedures
39 necessary to implement this subsection.

40 (6) Upon satisfactory proof provided by the conditional
41 licensee to the department that all conditions for licensure
42 have been met, the department shall convert the conditional
43 license into a license within 30 days.

44 * * *

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 2162 Session of
2026

INTRODUCED BY BOROWSKI, FRIEL, KUTZ, VENKAT, MAYES, MERSKI,
PIELLI, HILL-EVANS, PROBST, GUZMAN, BURGOS, SANCHEZ, BRENNAN,
MADDEN, CEPEDA-FREYTIZ, GALLAGHER, BOYD AND INGLIS,
JANUARY 28, 2026

REFERRED TO COMMITTEE ON HEALTH, JANUARY 28, 2026

AN ACT

1 Amending the act of December 14, 1992 (P.L.1116, No.145),
2 entitled "An act providing minimum standards, terms and
3 conditions for the licensing of persons who engage in
4 wholesale distributions in interstate commerce of
5 prescription drugs; and making a repeal," further providing
6 for definitions and for license application.

7 The General Assembly of the Commonwealth of Pennsylvania
8 hereby enacts as follows:

9 ~~Section 1. The definition of "virtual manufacturer" in~~
10 ~~section 3 of the act of December 14, 1992 (P.L.1116, No.145),~~
11 ~~known as the Wholesale Prescription Drug Distributors License~~
12 ~~Act, added October 16, 2024 (P.L.988, No.101), is amended to~~
13 ~~read:~~

14 Section 1. Section 3 of the act of December 14, 1992
15 (P.L.1116, No.145), known as the Wholesale Prescription Drug
16 Distributors License Act, is amended by adding a definition to
17 read:

18 Section 3. Definitions.

19 The following words and phrases when used in this act shall

A03371 Amendment in Context

1 have the meanings given to them in this section unless the
2 context clearly indicates otherwise:

3 * * *

4 ~~"Virtual manufacturer." A person with a place of business~~
5 ~~located in this Commonwealth in the business of manufacturing~~
6 ~~and distributing a drug or medical device that:~~

7 ~~(1) Holds the drug or device approval and label code or~~
8 ~~is otherwise identified on the product label from the United~~
9 ~~States Food and Drug Administration[.] or has submitted an~~
10 ~~application to the United States Food and Drug Administration~~
11 ~~for approval of the drug or device or intends to submit an~~
12 ~~application for approval within 12 months.~~

13 ~~(2) At no time takes physical possession of any drug or~~
14 ~~device in this Commonwealth.~~

15 ~~"Conditional license." A temporary license issued by the~~
16 ~~department to a manufacturer or a virtual manufacturer for a~~
17 ~~drug or medical device that has not yet received final approval~~
18 ~~from the United States Food and Drug Administration.~~

19 * * *

20 ~~Section 2. Section 5(a) of the act is amended by adding~~
21 ~~paragraphs to read:~~

22 ~~Section 5. License application.~~

23 ~~(a) Information on application. An applicant for a license~~
24 ~~shall provide the following information on a license application~~
25 ~~form approved by the department:~~

26 ~~* * *~~

27 ~~(6.2) If the applicant is a manufacturer of a~~
28 ~~prescription drug that has not been approved by the United~~
29 ~~States Food and Drug Administration, a statement that the~~
30 ~~applicant has submitted an application to the United States~~

A03371 Amendment in Context

~~Food and Drug Administration for approval of the prescription drug or that the applicant intends to submit an application for approval within 12 months. The department may not require approval of a prescription drug by the United States Food and Drug Administration as a condition of licensure under this act.~~

~~(6.3) If the applicant is a virtual manufacturer of a drug or medical device and does not hold the drug or device approval and label code or is not otherwise identified on the product label from the United States Food and Drug Administration, a statement that the applicant has submitted an application to the United States Food and Drug Administration for approval of the drug or device or that the applicant intends to submit an application for approval within 12 months. The department may not require approval of a drug or medical device by the United States Food and Drug Administration as a condition of licensure under this act.~~

~~* * *~~

Section 2. Section 5 of the act is amended by adding a subsection to read:

Section 5. License application.

~~* * *~~

~~(a.2) Conditional license.--~~

~~(1) If the applicant is a manufacturer of a prescription drug or a virtual manufacturer of a drug or medical device that has not yet received approval from the United States Food and Drug Administration, the department may issue a conditional license if the applicant submits all of the following:~~

~~(i) Documentation demonstrating that an application~~

A03371 Amendment in Context

1 for approval has been submitted to the United States Food
2 and Drug Administration, including, where applicable:
3 (A) a new drug application number;
4 (B) an abbreviated new drug application number;
5 (C) a biologics license application number;
6 (D) a unique device identification number; or
7 (E) other documentation acceptable to the
8 department demonstrating active review by the United
9 States Food and Drug Administration.
10 (ii) Documentation identifying any contract
11 manufacturing organization or licensed manufacturing
12 facility involved in the manufacture, packaging, labeling
13 or distribution of the drug or medical device.
14 (iii) Documentation demonstrating compliance with
15 applicable requirements of 21 U.S.C. Ch. 9 Subch. V Pt. H
16 (relating to pharmaceutical distribution supply chain).
17 (2) A conditional license issued under paragraph (1):
18 (i) shall expire one year after issuance unless
19 renewed by the department;
20 (ii) shall automatically expire upon denial,
21 withdrawal or refusal of the applicant's approval
22 application by the United States Food and Drug
23 Administration;
24 (iii) may not authorize commercial distribution of a
25 drug or device unless otherwise permitted under Federal
26 law; and
27 (iv) does not create a property interest in the
28 conditional license and may be suspended or revoked by
29 the department for failure to maintain compliance with
30 this act or applicable Federal law.

A03371 Amendment in Context

1 (3) An applicant issued a conditional license under
2 paragraph (1) shall notify the department within five
3 business days of:

4 (i) approval, denial, withdrawal or refusal of an
5 application by the United States Food and Drug
6 Administration; or

7 (ii) any material change to the applicant's
8 manufacturing or distribution arrangements.

9 (4) Issuance of a conditional license or a license under
10 this subsection may not be construed as approval, endorsement
11 or authorization of a drug or medical device by the
12 Commonwealth.

13 (5) The department may promulgate regulations and
14 develop monitoring, reporting and enforcement procedures
15 necessary to implement this subsection.

16 (6) Upon satisfactory proof provided by the conditional
17 licensee to the department that all conditions for licensure
18 have been met, the department shall convert the conditional
19 license into a license within 30 days.

20 * * *

21 Section 3. This act shall take effect in 60 days.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HB2341 PN3114	Prepared By:	Erika Fricke
Committee:	Health		717-908-7023
Sponsor:	Ortitay, Jason	Executive Director:	Erika Fricke
Date:	5/22/2026		

A. Brief Concept

The Department of Health shall contract with a security company to create a standardized risk assessment platform and provide grants to healthcare facilities to implement it.

C. Analysis of the Bill

HB2341 requires the Department of Health to select a single contractor to provide a standardized risk assessment platform for hospitals in the Commonwealth. The Department will then provide grants to hospitals to contract with the vendor for a risk assessment.

The Health Care Facility Grant Program contains two components.

Standardized threat assessment contract

The Department must contract with a single vendor for creation of a standardized threat and risk assessment platform. That platform must include:

- A threat and risk assessment framework specific to health care facilities
- Real time data-collection and reporting
- Workflow management for risk identification, mitigation planning and compliance
- Features that function across entities, such as public safety and health care, for tracking and monitoring.
- Any other capabilities required.

The contractor must be selected in a competitive bidding process, unless only one contractor exists. They must continue to provide services until all funds received have been spent and will be considered in breach of contract if they don't.

Grants to hospitals for use of risk platform

Hospitals can apply to DOH for a grant, and the Department must explain why they fund, don't fund, or partially fund the request. If a grant has been awarded, DOH and the facility must enter into a grant agreement including:

- Terms and conditions of the grant, including any reporting requirements
- Policies and procedures
- Authorization of the ability to electronically manage the program.

Within 90 days after the approval of a grant, the Department must provide the funds to purchase a standardized risk assessment. The grant must match the cost of the assessment. Grants must be renewed annually.

Health care facility requirements

Health care facilities must show that:

- The facility is licensed
- the facility will comply with program requirements - if they don't they will be removed and grant money may be recouped

Reporting

The Department must annually publish a report including:

- The contraction process
- The number of facilities that receive grants
- Amount of each grant
- Number of facilities using the standardized threat assessment platform
- When facilities got grants, but didn't use the platform
- Risk assessments conducted
- Corrective actions in response to risks
- Money distributed
- Information on money distributed, including county level data on facilities receiving funds
- How to improve the program

The report must be sent to the leaders of the Appropriations, Health and Human Services and Health committees in the House and Senate.

Once the program is finished, the Department must submit a final report.

Effective Date:

Immediately.

G. Relevant Existing Laws

None

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

n/a

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 2341 Session of 2026

INTRODUCED BY ORTITAY, MEHAFFIE, KUZMA AND CIRESI,
MARCH 31, 2026

REFERRED TO COMMITTEE ON HEALTH, MARCH 31, 2026

AN ACT

1 Amending the act of April 9, 1929 (P.L.343, No.176), entitled
 2 "An act relating to the finances of the State government;
 3 providing for cancer control, prevention and research, for
 4 ambulatory surgical center data collection, for the Joint
 5 Underwriting Association, for entertainment business
 6 financial management firms, for private dam financial
 7 assurance and for reinstatement of item vetoes; providing for
 8 the settlement, assessment, collection, and lien of taxes,
 9 bonus, and all other accounts due the Commonwealth, the
 10 collection and recovery of fees and other money or property
 11 due or belonging to the Commonwealth, or any agency thereof,
 12 including escheated property and the proceeds of its sale,
 13 the custody and disbursement or other disposition of funds
 14 and securities belonging to or in the possession of the
 15 Commonwealth, and the settlement of claims against the
 16 Commonwealth, the resettlement of accounts and appeals to the
 17 courts, refunds of moneys erroneously paid to the
 18 Commonwealth, auditing the accounts of the Commonwealth and
 19 all agencies thereof, of all public officers collecting
 20 moneys payable to the Commonwealth, or any agency thereof,
 21 and all receipts of appropriations from the Commonwealth,
 22 authorizing the Commonwealth to issue tax anticipation notes
 23 to defray current expenses, implementing the provisions of
 24 section 7(a) of Article VIII of the Constitution of
 25 Pennsylvania authorizing and restricting the incurring of
 26 certain debt and imposing penalties; affecting every
 27 department, board, commission, and officer of the State
 28 government, every political subdivision of the State, and
 29 certain officers of such subdivisions, every person,
 30 association, and corporation required to pay, assess, or
 31 collect taxes, or to make returns or reports under the laws
 32 imposing taxes for State purposes, or to pay license fees or
 33 other moneys to the Commonwealth, or any agency thereof,
 34 every State depository and every debtor or creditor of the

1 Commonwealth," establishing the Health Care Facility Threat
2 Assessment Grant Program; and imposing duties on the
3 Department of Health.

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. The act of April 9, 1929 (P.L.343, No.176), known
7 as The Fiscal Code, is amended by adding an article to read:

8 ARTICLE I-M

9 HEALTH CARE FACILITY THREAT

10 ASSESSMENT GRANT PROGRAM

11 Section 101-M. Definitions.

12 The following words and phrases when used in this article
13 shall have the meanings given to them in this section unless the
14 context clearly indicates otherwise:

15 "Contract." A contract with the department for the provision
16 of a standardized threat and risk assessment platform under this
17 article.

18 "Contractor." A person who enters into a contract with the
19 department under section 103-M(b).

20 "Department." The Department of Health of the Commonwealth.

21 "Grant." An award of money by the department to a health
22 care facility under section 104-M.

23 "Health care facility." As defined in section 802.1 of the
24 act of July 19, 1979 (P.L.130, No.48), known as the Health Care
25 Facilities Act.

26 "Program." The Health Care Facility Threat Assessment Grant
27 Program established under section 102-M.

28 Section 102-M. Establishment of program.

29 The Health Care Facility Threat Assessment Grant Program is
30 established within the department to improve safety and security
31 in health care facilities through the procurement and deployment

1 of a standardized threat and risk assessment platform. The
2 department shall implement the program.

3 Section 103-M. Use of funds.

4 (a) Exclusive use.--Money appropriated to the department for
5 the program shall be used exclusively for the implementation of
6 the program.

7 (b) Platform.--The department shall expend money
8 appropriated to the department for the program to contract with
9 a contractor for the provision of a standardized threat and risk
10 assessment platform. The platform shall include the following
11 capabilities:

12 (1) A structured threat and risk assessment framework
13 tailored to health care facility operations.

14 (2) Real-time data collection and digital reporting
15 tools.

16 (3) Workflow management tools for risk identification,
17 mitigation planning and compliance monitoring.

18 (4) Collaborative features for use by health care
19 facilities, health care administrators and public safety
20 stakeholders to conduct standardized evaluations, track
21 corrective actions and generate comprehensive reports for
22 informed decision making.

23 (5) Any additional capabilities determined by the
24 department to be necessary for the purpose of this article.

25 (c) Contractor selection.--Subject to 62 Pa.C.S. Ch. 5
26 (relating to source selection and contract formation), the
27 department shall utilize a competitive bidding process to select
28 a contractor, unless the department determines that only one
29 contractor has the capacity and willingness to perform the
30 duties under this article.

1 (d) Contractor obligations.--A contractor shall remain
2 obligated to perform in accordance with the terms of the
3 contract until all money obligated to the contractor under the
4 contract has been fully expended, notwithstanding the exhaustion
5 of money appropriated to the department for the program during a
6 fiscal year.

7 (e) Breach of contract.--A contractor who fails to perform
8 in accordance with the terms of the contract shall be deemed in
9 breach of contract, and the applicable contractual remedies
10 relating to the breach shall apply.

11 (f) Award of grants.--The department shall expend money
12 appropriated to the department for the program to award grants
13 to health care facilities under section 104-M.

14 Section 104-M. Grants to health care facilities.

15 (a) Application.--A health care facility may apply to the
16 department for a grant under the program in a form and manner
17 determined by the department. Applications shall be made
18 available electronically and shall include documentation as
19 required by the department.

20 (b) Review.--Upon receipt of an application, the department
21 shall review the application and may approve or disapprove the
22 application or award an amount less than requested in the
23 application. The department shall provide a written explanation
24 to the health care facility for a disapproval or a partial grant
25 award.

26 (c) Grant agreements.--Upon approving an application under
27 subsection (b), the department may not disburse a grant award
28 until the department and the health care facility enter into a
29 fully executed grant agreement. The agreement shall include the
30 following:

1 (1) Terms and conditions of the grant, including
2 applicable Federal and State laws and reporting requirements.

3 (2) Departmental policies and procedures applicable to
4 the program.

5 (3) Authorization for electronic execution by all
6 parties.

7 (d) Award and use.--

8 (1) The department shall disburse an approved grant
9 award to the health care facility no later than 90 days from
10 the date of application approval under subsection (b).

11 (2) A grant award shall be used exclusively by a health
12 care facility to procure a standardized threat and risk
13 assessment platform from a contractor under section 103-M(c).
14 A grant award shall not exceed the cost incurred by a health
15 care facility to procure a standardized threat and risk
16 assessment platform from a contractor under section 103-M(c).

17 (e) Annual requirements.--In order to receive a grant in
18 each calendar year the program is operational, a health care
19 facility must annually apply to the department for a grant in
20 accordance with subsection (a).

21 Section 105-M. Certification requirements for health care
22 facilities.

23 In a form and manner determined by the department, a health
24 care facility applying for a grant under the program shall
25 certify that:

26 (1) the health care facility is licensed by the
27 department and in good standing;

28 (2) the health care facility agrees to comply with the
29 requirements of the program;

30 (3) failure to comply with program requirements:

1 (i) shall result in removal from the program; and
2 (ii) may result in recoupment of grant money; and
3 (4) the information provided in the application and
4 supporting documents and forms are true and correct in all
5 material respects. An authorized representative of a health
6 care facility who knowingly provides false information shall
7 be subject to 18 Pa.C.S. § 4904 (relating to unsworn
8 falsification to authorities).

9 Section 106-M. Reporting.

10 (a) Annual report.--No later than December 31 of the year
11 after the effective date of this subsection and by December 31
12 of each year thereafter, the department shall publish a report
13 on its publicly accessible Internet website on the program. The
14 report shall include all of the following information:

15 (1) A description of the contracting process and the
16 contractor selected by the department under section 104-M.

17 (2) The number and type of health care facilities that
18 received grants under the program.

19 (3) The amount of each grant awarded under the program.

20 (4) The number and type of health care facilities
21 utilizing the standardized threat and risk assessment
22 platform from the contractor under section 103-M(c).

23 (5) Any instances when health care facilities received
24 grants but failed to utilize the standardized threat and risk
25 assessment platform from the contractor under section 103-
26 M(c).

27 (6) A summary of risk assessments conducted by health
28 care facilities that received grants under the program.

29 (7) A summary of corrective actions initiated by health
30 care facilities in response to risk assessments conducted

1 under the program.

2 (8) The total amount of money distributed under the
3 program during the preceding calendar year.

4 (9) An aggregate total, by county, of health care
5 facilities receiving grants under the program.

6 (10) Recommendations for improving the administration or
7 effectiveness of the program.

8 (b) Submission.--The department shall submit the report
9 under subsection (a) to all of the following:

10 (1) The chairperson and minority chairperson of the
11 Appropriations Committee of the Senate.

12 (2) The chairperson and minority chairperson of the
13 Appropriations Committee of the House of Representatives.

14 (3) The chairperson and minority chairperson of the
15 Health and Human Services Committee of the Senate.

16 (4) The chairperson and minority chairperson of the
17 Health Committee of the House of Representatives.

18 (c) Final report.--Upon the cessation of the program,
19 including the full disbursement of all money appropriated to the
20 department for the program and the termination of grant
21 activity, the department shall publish and submit a final report
22 in accordance with this section.

23 Section 2. This act shall take effect immediately.

LEGISLATIVE REFERENCE BUREAU

AMENDMENTS TO HOUSE BILL NO. 2341

Sponsor:

Printer's No. 3114

1 Amend Bill, page 2, lines 1 through 3, by striking out
2 "Health Care Facility Threat" in line 1 and all of lines 2 and 3
3 and inserting

4 Hospital Security Grant Fund; and imposing duties on the
5 Pennsylvania Commission on Crime and Delinquency.

6 Amend Bill, page 2, lines 9 and 10, by striking out all of
7 said lines and inserting

8 HOSPITAL SECURITY GRANT FUND

9 Amend Bill, page 2, lines 15 through 31; pages 3 through 6,
10 lines 1 through 30; page 7, lines 1 through 22; by striking out
11 all of said lines on said pages and inserting

12 "Commission." The Pennsylvania Commission on Crime and
13 Delinquency.

14 "Eligible applicant." A nonprofit hospital that is an exempt
15 organization as defined under 26 U.S.C. § 501(c)(3) (relating to
16 exemption from tax on corporations, certain trusts, etc.).

17 "Eligible project." Security enhancements designed to
18 protect the safety and security of patients, employers,
19 employees, visitors and users of a hospital located in this
20 Commonwealth, including conducting physical security
21 assessments.

22 "Fund." The Hospital Security Grant Fund established under
23 section 102-M.

24 "Hospital." The term shall mean the same as defined under
25 section 802.1 of the act of July 19, 1979 (P.L.130, No.48),
26 known as the Health Care Facilities Act.

27 "Physical security assessment." A strategic evaluation of a
28 hospital's facilities, programs and operational procedures used
29 to identify potential security threats conducted by the
30 Pennsylvania State Police Risk and Vulnerability Assessment Team
31 or other professional physical security assessment experts.

32 "Security enhancement." The term includes:

33 (1) Safety and security planning, including a physical

1 security assessment.

2 (2) Purchase of safety and security equipment.

3 (3) Purchase of security-related technology, which may
4 include:

5 (i) Metal detectors.

6 (ii) Protective lighting.

7 (iii) Surveillance equipment.

8 (iv) Special emergency communications equipment.

9 (v) Electronic locksets.

10 (vi) Deadbolts.

11 (vii) Trauma kits.

12 (viii) Theft-control devices.

13 (4) Safety and security training.

14 (5) Threat awareness and response training.

15 (6) Upgrades to existing structures that enhance safety
16 and security.

17 (7) Vulnerability and threat assessments.

18 (8) Specialty trained canines.

19 (9) Other safety-related or security-related project
20 that enhances the safety or security of a hospital.

21 Section 102-M. Establishment.

22 The Hospital Security Grant Fund is established within the
23 State Treasury. The purpose of the money in the fund shall be to
24 improve safety and security in hospitals.

25 Section 103-M. Use of funds.

26 (a) Award of grants.--The commission shall expend money
27 appropriated to the commission by the General Assembly for the
28 fund to award grants to hospitals under section 104-M.

29 (b) Exclusive use.--Money, including appropriated money and
30 accrued interest, deposited into the fund shall be appropriated
31 on a continuing basis to the commission and used exclusively by
32 the commission for grants under this article.

33 Section 104-M. Administration of fund.

34 (a) Application.--An eligible applicant may apply to the
35 commission for a grant from the fund in a form and manner
36 determined by the commission. Applications shall be made
37 available electronically and shall include documentation as
38 required by the commission.

39 (b) Review.--The commission, in consultation with the
40 Governor's Office of Homeland Security, the Department of Health
41 and the Pennsylvania State Police, shall review completed
42 applications received.

43 (c) Allocation.--A grant from the fund shall not exceed
44 \$150,000 per fiscal year for eligible projects.

45 (d) Limitations.--The following shall apply to grants
46 awarded from the fund:

47 (1) The commission may not provide grants in excess of
48 the amount in the fund.

49 (2) The commission may prorate a grant amount to an
50 eligible applicant.

51 (3) Grant money allocated from the fund shall be used to

1 supplement and not supplant existing money.

2 (e) Eligible projects.--The commission may only award grants
3 from the fund for eligible projects. Eligible applicants may
4 only expend grant money received from the fund on eligible
5 projects.

6 (f) Eligibility for redevelopment assistance capital
7 project.--

8 (1) An eligible project that receives a grant under this
9 article may be the subject of an award for a redevelopment
10 assistance capital project under Chapter 3 of the act of
11 February 9, 1999 (P.L.1, No.1), known as the Capital
12 Facilities Debt Enabling Act.

13 (2) Nothing in this subsection shall be construed to
14 modify the eligibility requirements for redevelopment
15 assistance capital projects under the Capital Facilities Debt
16 Enabling Act.

17 (g) Administrative expenses.--The commission may not expend
18 more than 3% of money appropriated to the commission for the
19 fund on administrative expenses.

20 (h) Application periods.--The commission shall establish
21 application periods for the submission of applications for a
22 grant.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILLNo. **2341** Session of
2026INTRODUCED BY ORTITAY, MEHAFFIE, KUZMA AND CIRESI,
MARCH 31, 2026

REFERRED TO COMMITTEE ON HEALTH, MARCH 31, 2026

AN ACT

1 Amending the act of April 9, 1929 (P.L.343, No.176), entitled
2 "An act relating to the finances of the State government;
3 providing for cancer control, prevention and research, for
4 ambulatory surgical center data collection, for the Joint
5 Underwriting Association, for entertainment business
6 financial management firms, for private dam financial
7 assurance and for reinstatement of item vetoes; providing for
8 the settlement, assessment, collection, and lien of taxes,
9 bonus, and all other accounts due the Commonwealth, the
10 collection and recovery of fees and other money or property
11 due or belonging to the Commonwealth, or any agency thereof,
12 including escheated property and the proceeds of its sale,
13 the custody and disbursement or other disposition of funds
14 and securities belonging to or in the possession of the
15 Commonwealth, and the settlement of claims against the
16 Commonwealth, the resettlement of accounts and appeals to the
17 courts, refunds of moneys erroneously paid to the
18 Commonwealth, auditing the accounts of the Commonwealth and
19 all agencies thereof, of all public officers collecting
20 moneys payable to the Commonwealth, or any agency thereof,
21 and all receipts of appropriations from the Commonwealth,
22 authorizing the Commonwealth to issue tax anticipation notes
23 to defray current expenses, implementing the provisions of
24 section 7(a) of Article VIII of the Constitution of
25 Pennsylvania authorizing and restricting the incurring of
26 certain debt and imposing penalties; affecting every
27 department, board, commission, and officer of the State
28 government, every political subdivision of the State, and
29 certain officers of such subdivisions, every person,
30 association, and corporation required to pay, assess, or
31 collect taxes, or to make returns or reports under the laws
32 imposing taxes for State purposes, or to pay license fees or
33 other moneys to the Commonwealth, or any agency thereof,
34 every State depository and every debtor or creditor of the

A03394 Amendment in Context

Commonwealth," ~~establishing the Health Care Facility Threat Assessment Grant Program; and imposing duties on the Department of Health.~~ Hospital Security Grant Fund; and imposing duties on the Pennsylvania Commission on Crime and Delinquency.

The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:

Section 1. The act of April 9, 1929 (P.L.343, No.176), known as The Fiscal Code, is amended by adding an article to read:

ARTICLE I-M

HEALTH CARE FACILITY THREAT

ASSESSMENT GRANT PROGRAM

HOSPITAL SECURITY GRANT FUND

Section 101-M. Definitions.

The following words and phrases when used in this article shall have the meanings given to them in this section unless the context clearly indicates otherwise:

~~"Contract." A contract with the department for the provision of a standardized threat and risk assessment platform under this article.~~

~~"Contractor." A person who enters into a contract with the department under section 103 M(b).~~

~~"Department." The Department of Health of the Commonwealth.~~

~~"Grant." An award of money by the department to a health care facility under section 104 M.~~

~~"Health care facility." As defined in section 802.1 of the act of July 19, 1979 (P.L.130, No.48), known as the Health Care Facilities Act.~~

~~"Program." The Health Care Facility Threat Assessment Grant Program established under section 102 M.~~

~~Section 102 M. Establishment of program.~~

~~The Health Care Facility Threat Assessment Grant Program is~~

A03394 Amendment in Context

~~established within the department to improve safety and security in health care facilities through the procurement and deployment of a standardized threat and risk assessment platform. The department shall implement the program.~~

~~Section 103 M. Use of funds.~~

~~(a) Exclusive use. Money appropriated to the department for the program shall be used exclusively for the implementation of the program.~~

~~(b) Platform. The department shall expend money appropriated to the department for the program to contract with a contractor for the provision of a standardized threat and risk assessment platform. The platform shall include the following capabilities:~~

~~(1) A structured threat and risk assessment framework tailored to health care facility operations.~~

~~(2) Real time data collection and digital reporting tools.~~

~~(3) Workflow management tools for risk identification, mitigation planning and compliance monitoring.~~

~~(4) Collaborative features for use by health care facilities, health care administrators and public safety stakeholders to conduct standardized evaluations, track corrective actions and generate comprehensive reports for informed decision making.~~

~~(5) Any additional capabilities determined by the department to be necessary for the purpose of this article.~~

~~(c) Contractor selection. Subject to 62 Pa.C.S. Ch. 5 (relating to source selection and contract formation), the department shall utilize a competitive bidding process to select a contractor, unless the department determines that only one~~

A03394 Amendment in Context

1 ~~contractor has the capacity and willingness to perform the~~
2 ~~duties under this article.~~

3 ~~(d) Contractor obligations.—A contractor shall remain~~
4 ~~obligated to perform in accordance with the terms of the~~
5 ~~contract until all money obligated to the contractor under the~~
6 ~~contract has been fully expended, notwithstanding the exhaustion~~
7 ~~of money appropriated to the department for the program during a~~
8 ~~fiscal year.~~

9 ~~(e) Breach of contract.—A contractor who fails to perform~~
10 ~~in accordance with the terms of the contract shall be deemed in~~
11 ~~breach of contract, and the applicable contractual remedies~~
12 ~~relating to the breach shall apply.~~

13 ~~(f) Award of grants.—The department shall expend money~~
14 ~~appropriated to the department for the program to award grants~~
15 ~~to health care facilities under section 104 M.~~

16 ~~Section 104 M. Grants to health care facilities.~~

17 ~~(a) Application.—A health care facility may apply to the~~
18 ~~department for a grant under the program in a form and manner~~
19 ~~determined by the department. Applications shall be made~~
20 ~~available electronically and shall include documentation as~~
21 ~~required by the department.~~

22 ~~(b) Review.—Upon receipt of an application, the department~~
23 ~~shall review the application and may approve or disapprove the~~
24 ~~application or award an amount less than requested in the~~
25 ~~application. The department shall provide a written explanation~~
26 ~~to the health care facility for a disapproval or a partial grant~~
27 ~~award.~~

28 ~~(c) Grant agreements.—Upon approving an application under~~
29 ~~subsection (b), the department may not disburse a grant award~~
30 ~~until the department and the health care facility enter into a~~

A03394 Amendment in Context

1 ~~fully executed grant agreement. The agreement shall include the~~
2 ~~following:~~

3 ~~(1) Terms and conditions of the grant, including~~
4 ~~applicable Federal and State laws and reporting requirements.~~

5 ~~(2) Departmental policies and procedures applicable to~~
6 ~~the program.~~

7 ~~(3) Authorization for electronic execution by all~~
8 ~~parties.~~

9 ~~(d) Award and use.~~

10 ~~(1) The department shall disburse an approved grant~~
11 ~~award to the health care facility no later than 90 days from~~
12 ~~the date of application approval under subsection (b).~~

13 ~~(2) A grant award shall be used exclusively by a health~~
14 ~~care facility to procure a standardized threat and risk~~
15 ~~assessment platform from a contractor under section 103 M(c).~~

16 ~~A grant award shall not exceed the cost incurred by a health~~
17 ~~care facility to procure a standardized threat and risk~~
18 ~~assessment platform from a contractor under section 103 M(c).~~

19 ~~(e) Annual requirements. In order to receive a grant in~~
20 ~~each calendar year the program is operational, a health care~~
21 ~~facility must annually apply to the department for a grant in~~
22 ~~accordance with subsection (a).~~

23 ~~Section 105 M. Certification requirements for health care~~
24 ~~facilities.~~

25 ~~In a form and manner determined by the department, a health~~
26 ~~care facility applying for a grant under the program shall~~
27 ~~certify that:~~

28 ~~(1) the health care facility is licensed by the~~
29 ~~department and in good standing;~~

30 ~~(2) the health care facility agrees to comply with the~~

A03394 Amendment in Context

1 ~~requirements of the program;~~

2 ~~(3) failure to comply with program requirements;~~

3 ~~(i) shall result in removal from the program; and~~

4 ~~(ii) may result in recoupment of grant money; and~~

5 ~~(4) the information provided in the application and~~
6 ~~supporting documents and forms are true and correct in all~~
7 ~~material respects. An authorized representative of a health~~
8 ~~care facility who knowingly provides false information shall~~
9 ~~be subject to 18 Pa.C.S. § 4904 (relating to unsworn~~
10 ~~falsification to authorities).~~

11 ~~Section 106 M. Reporting.~~

12 ~~(a) Annual report. No later than December 31 of the year~~
13 ~~after the effective date of this subsection and by December 31~~
14 ~~of each year thereafter, the department shall publish a report~~
15 ~~on its publicly accessible Internet website on the program. The~~
16 ~~report shall include all of the following information:~~

17 ~~(1) A description of the contracting process and the~~
18 ~~contractor selected by the department under section 104 M.~~

19 ~~(2) The number and type of health care facilities that~~
20 ~~received grants under the program.~~

21 ~~(3) The amount of each grant awarded under the program.~~

22 ~~(4) The number and type of health care facilities~~
23 ~~utilizing the standardized threat and risk assessment~~
24 ~~platform from the contractor under section 103 M(c).~~

25 ~~(5) Any instances when health care facilities received~~
26 ~~grants but failed to utilize the standardized threat and risk~~
27 ~~assessment platform from the contractor under section 103~~
28 ~~M(c).~~

29 ~~(6) A summary of risk assessments conducted by health~~
30 ~~care facilities that received grants under the program.~~

A03394 Amendment in Context

1 ~~(7) A summary of corrective actions initiated by health~~
2 ~~care facilities in response to risk assessments conducted~~
3 ~~under the program.~~

4 ~~(8) The total amount of money distributed under the~~
5 ~~program during the preceding calendar year.~~

6 ~~(9) An aggregate total, by county, of health care~~
7 ~~facilities receiving grants under the program.~~

8 ~~(10) Recommendations for improving the administration or~~
9 ~~effectiveness of the program.~~

10 ~~(b) Submission. The department shall submit the report~~
11 ~~under subsection (a) to all of the following:~~

12 ~~(1) The chairperson and minority chairperson of the~~
13 ~~Appropriations Committee of the Senate.~~

14 ~~(2) The chairperson and minority chairperson of the~~
15 ~~Appropriations Committee of the House of Representatives.~~

16 ~~(3) The chairperson and minority chairperson of the~~
17 ~~Health and Human Services Committee of the Senate.~~

18 ~~(4) The chairperson and minority chairperson of the~~
19 ~~Health Committee of the House of Representatives.~~

20 ~~(c) Final report. Upon the cessation of the program,~~
21 ~~including the full disbursement of all money appropriated to the~~
22 ~~department for the program and the termination of grant~~
23 ~~activity, the department shall publish and submit a final report~~
24 ~~in accordance with this section.~~

25 ~~"Commission." The Pennsylvania Commission on Crime and~~
26 ~~Delinquency.~~

27 ~~"Eligible applicant." A nonprofit hospital that is an exempt~~
28 ~~organization as defined under 26 U.S.C. § 501(c) (3) (relating to~~
29 ~~exemption from tax on corporations, certain trusts, etc.).~~

30 ~~"Eligible project." Security enhancements designed to~~

A03394 Amendment in Context

1 protect the safety and security of patients, employers,
2 employees, visitors and users of a hospital located in this
3 Commonwealth, including conducting physical security
4 assessments.

5 "Fund." The Hospital Security Grant Fund established under
6 section 102-M.

7 "Hospital." The term shall mean the same as defined under
8 section 802.1 of the act of July 19, 1979 (P.L.130, No.48),
9 known as the Health Care Facilities Act.

10 "Physical security assessment." A strategic evaluation of a
11 hospital's facilities, programs and operational procedures used
12 to identify potential security threats conducted by the
13 Pennsylvania State Police Risk and Vulnerability Assessment Team
14 or other professional physical security assessment experts.

15 "Security enhancement." The term includes:

16 (1) Safety and security planning, including a physical
17 security assessment.

18 (2) Purchase of safety and security equipment.

19 (3) Purchase of security-related technology, which may
20 include:

21 (i) Metal detectors.

22 (ii) Protective lighting.

23 (iii) Surveillance equipment.

24 (iv) Special emergency communications equipment.

25 (v) Electronic locksets.

26 (vi) Deadbolts.

27 (vii) Trauma kits.

28 (viii) Theft-control devices.

29 (4) Safety and security training.

30 (5) Threat awareness and response training.

A03394 Amendment in Context

1 (6) Upgrades to existing structures that enhance safety
2 and security.

3 (7) Vulnerability and threat assessments.

4 (8) Specialty trained canines.

5 (9) Other safety-related or security-related project
6 that enhances the safety or security of a hospital.

7 Section 102-M. Establishment.

8 The Hospital Security Grant Fund is established within the
9 State Treasury. The purpose of the money in the fund shall be to
10 improve safety and security in hospitals.

11 Section 103-M. Use of funds.

12 (a) Award of grants.--The commission shall expend money
13 appropriated to the commission by the General Assembly for the
14 fund to award grants to hospitals under section 104-M.

15 (b) Exclusive use.--Money, including appropriated money and
16 accrued interest, deposited into the fund shall be appropriated
17 on a continuing basis to the commission and used exclusively by
18 the commission for grants under this article.

19 Section 104-M. Administration of fund.

20 (a) Application.--An eligible applicant may apply to the
21 commission for a grant from the fund in a form and manner
22 determined by the commission. Applications shall be made
23 available electronically and shall include documentation as
24 required by the commission.

25 (b) Review.--The commission, in consultation with the
26 Governor's Office of Homeland Security, the Department of Health
27 and the Pennsylvania State Police, shall review completed
28 applications received.

29 (c) Allocation.--A grant from the fund shall not exceed
30 \$150,000 per fiscal year for eligible projects.

A03394 Amendment in Context

1 (d) Limitations.--The following shall apply to grants
2 awarded from the fund:

3 (1) The commission may not provide grants in excess of
4 the amount in the fund.

5 (2) The commission may prorate a grant amount to an
6 eligible applicant.

7 (3) Grant money allocated from the fund shall be used to
8 supplement and not supplant existing money.

9 (e) Eligible projects.--The commission may only award grants
10 from the fund for eligible projects. Eligible applicants may
11 only expend grant money received from the fund on eligible
12 projects.

13 (f) Eligibility for redevelopment assistance capital
14 project.--

15 (1) An eligible project that receives a grant under this
16 article may be the subject of an award for a redevelopment
17 assistance capital project under Chapter 3 of the act of
18 February 9, 1999 (P.L.1, No.1), known as the Capital
19 Facilities Debt Enabling Act.

20 (2) Nothing in this subsection shall be construed to
21 modify the eligibility requirements for redevelopment
22 assistance capital projects under the Capital Facilities Debt
23 Enabling Act.

24 (g) Administrative expenses.--The commission may not expend
25 more than 3% of money appropriated to the commission for the
26 fund on administrative expenses.

27 (h) Application periods.--The commission shall establish
28 application periods for the submission of applications for a
29 grant.

30 Section 2. This act shall take effect immediately.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HB1365 PN1559	Prepared By:	Patrick O'Rourke (717) 787-4296
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Delloso, David		
Date:	6/1/2026		

A. Brief Concept

Establishes the Medication-Induced Movement Disorders (MIMD) Screening Education Program (MIMDSEP) to provide guidance and resources for MIMD.

C. Analysis of the Bill

Amends (Title 35 Health and Safety) to add Chapter 56A (Public Health Notification Programs) which establishes MIMDSEP within the Department of Health (DOH), with additional consultation coming from the following agencies:

- 1) Department of Aging.
- 2) Department of Drug and Alcohol Programs.
- 3) Office of Developmental Programs, Department of Human Services.
- 4) Office of Mental Health and Substance Abuse Services, Department of Human Services.
- 5) Bureau of Community Corrections, Department of Corrections.

The program shall include:

- Information to highlight the importance of screening for and identifying symptoms of MIMD associated with prolonged use of medications commonly used for the treatment of mental health materials.
- Guidance and educational materials for healthcare providers on clinical standards and best practices for screening and treating MIMD with guidance informed by the American Psychiatric Association and other relevant professional society practice guidelines, and developed in consultation with relevant healthcare provider groups.
- Education and outreach on the elimination of stigma for individuals with MIMD relating to the treatment of mental health conditions, including MIMD awareness materials for public safety officers.

DOH must develop and post informational materials on the department's publicly accessible website and distribute guidance and educational materials to healthcare providers and facilities in PA serving populations at high risk for MIMD, and promulgate regulations as needed for implementation and administration.

Effective Date:

60 days.

G. Relevant Existing Laws

42 CFR §483.5 sets out the formal definitions that apply to Medicare and Medicaid rules for long-term care facilities, clarifying the meaning of key terms related to resident protection, staff responsibilities, and facility structure to promote consistent standards of care.

21 C.F.R. § 201 provides requirements to list side effects and requirements on content and format of labeling for human prescription drugs and biological products, including warning and precautions, and adverse reactions.

Section 2102 of the Administrative Code of 1929 provides DOH with powers and duties to protect the health of people in Pennsylvania, and determine and employ the most efficient, practical means to prevent and suppress the spread of diseases.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2023-24 Legislative Session

- [HB 2650, PN 3799](#) (Schlossberg)
 - Referred to House Health Committee on 10/23/2024 and did not receive a vote.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1365 Session of
2025

INTRODUCED BY DELLOSO, APRIL 30, 2025

REFERRED TO COMMITTEE ON HEALTH, MAY 1, 2025

AN ACT

1 Amending Title 35 (Health and Safety) of the Pennsylvania
2 Consolidated Statutes, providing for public health
3 notification programs; and establishing the Medication-
4 Induced Movement Disorders Screening Education Program.

5 The General Assembly of the Commonwealth of Pennsylvania
6 hereby enacts as follows:

7 Section 1. Title 35 of the Pennsylvania Consolidated
8 Statutes is amended by adding a chapter to read:

9 CHAPTER 56A

10 PUBLIC HEALTH NOTIFICATION PROGRAMS

11 Subchapter

12 A. (Reserved)

13 B. Medication-Induced Movement Disorders Screening Education
14 Program

15 SUBCHAPTER A

16 (Reserved)

17 SUBCHAPTER B

18 MEDICATION-INDUCED MOVEMENT DISORDERS

19 SCREENING EDUCATION PROGRAM

1 Sec.

2 56A21. Definitions.

3 56A22. Medication-Induced Movement Disorders Screening

4 Education Program.

5 56A23. Regulations.

6 § 56A21. Definitions.

7 The following words and phrases when used in this subchapter
8 shall have the meanings given to them in this section unless the
9 context clearly indicates otherwise:

10 "Department." The Department of Health of the Commonwealth.

11 "Medication-induced movement disorders." A range of
12 neurological conditions characterized by involuntary abnormal
13 movements associated with prolonged use of certain medications
14 that are commonly used for the treatment of mental health
15 conditions.

16 "Program." The Medication-Induced Movement Disorders
17 Screening Education Program established under section 56A22(a)
18 (relating to Medication-Induced Movement Disorders Screening
19 Education Program).

20 § 56A22. Medication-Induced Movement Disorders Screening
21 Education Program.

22 (a) Establishment.--The Medication-Induced Movement
23 Disorders Screening Education Program is established in the
24 department.

25 (b) Development.--The department shall develop the program
26 for residents of this Commonwealth in consultation with relevant
27 agencies, including:

28 (1) The Office of Developmental Programs under the
29 Department of Human Services.

30 (2) The Office of Mental Health and Substance Abuse

1 Services under the Department of Human Services.

2 (3) The Department of Aging.

3 (4) The Department of Drug and Alcohol Programs.

4 (5) The Bureau of Community Corrections under the
5 Department of Corrections.

6 (c) Components.--The program must include:

7 (1) Educational information on the importance of
8 screening for and identifying symptoms of medication-induced
9 movement disorders associated with prolonged use of certain
10 medications that are commonly used for the treatment of
11 mental health conditions.

12 (2) The development of guidance and educational
13 materials for health care providers on clinical standards and
14 best practices for screening and treating medication-induced
15 movement disorders, including for services provided through
16 telehealth. The guidance shall be:

17 (i) Informed by the American Psychiatric Association
18 and other relevant and current professional society
19 practice guidelines.

20 (ii) Developed in coordination with relevant health
21 care provider groups.

22 (3) Education and outreach on the elimination of stigma
23 for individuals living with medication-induced movement
24 disorders related to the treatment of mental health
25 conditions, including medication-induced movement disorder
26 awareness materials for public safety officers.

27 (d) Electronic informational materials.--The department
28 shall develop electronic informational materials and make
29 available to the public and to health care providers information
30 regarding symptoms of, screenings for and treatment of

1 medication-induced movement disorders.

2 (e) Dissemination of informational materials.--The
3 department shall:

4 (1) Post the informational materials under subsection
5 (d) on the publicly accessible Internet website of the
6 department.

7 (2) Distribute the guidance and educational information
8 under subsection (c) to health care providers and facilities
9 in this Commonwealth serving populations at high risk of
10 medication-induced movement disorders.

11 § 56A23. Regulations.

12 The department shall promulgate regulations necessary to
13 implement and administer this subchapter.

14 Section 2. This act shall take effect in 60 days.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0475 PN3258	Prepared By:	Patrick O'Rourke (717) 787-4296
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Rivera, Nikki		
Date:	5/28/2026		

A. Brief Concept

Recognizes September "ITP Awareness Month."

C. Analysis of the Bill

Immune thrombocytopenia (ITP), a rare autoimmune disorder that causes low platelet counts, leading to bruising, bleeding, fatigue, and in severe cases, life-threatening hemorrhages. ITP is difficult to diagnose due to the lack of a specific test or known cause, and that the disease can vary in duration (newly diagnosed, persistent, or chronic) with no predictable timeline or guaranteed treatment. Management may include transfusions, medications, or even spleen removal, with outcomes differing widely among patients. More than 50,000 Americans live with ITP, with higher prevalence among women ages 30–60, and that the condition often requires lifestyle adjustments.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 475 Session of
2026

INTRODUCED BY RIVERA, FREEMAN, GUZMAN, VENKAT, SANCHEZ, HILL-
EVANS, CEPEDA-FREYTIZ, HOHENSTEIN, NEILSON AND PASHINSKI,
APRIL 22, 2026

REFERRED TO COMMITTEE ON HEALTH, APRIL 22, 2026

A RESOLUTION

1 Recognizing the month of September 2026 as "ITP Awareness Month"
2 in Pennsylvania.

3 WHEREAS, Immune thrombocytopenia, otherwise known as ITP, is
4 a rare autoimmune disease that causes an individual to have a
5 low platelet count, which may cause bruising, bleeding and
6 fatigue; and

7 WHEREAS, In severe cases, individuals can experience brain
8 bleeds or bleeding from their mouth, nose and gums; and

9 WHEREAS, The Platelet Disorder Support Association observes
10 September as "ITP Awareness Month" annually to raise awareness,
11 enhance research and develop better outcomes for individuals
12 living with ITP; and

13 WHEREAS, Diagnosing ITP is difficult because there is not a
14 specific test to identify it or a specific cause for how it
15 develops; and

16 WHEREAS, Diagnosis may include a physical examination, blood
17 smears, bone marrow examination or other blood tests; and

1 WHEREAS, The three phases of ITP are newly diagnosed ITP,
2 persistent ITP and chronic ITP, each with numerous symptoms and
3 side effects and classified by the length of time a person has
4 had the condition; and

5 WHEREAS, Unlike other diseases there is no estimated timeline
6 for how long ITP will last, as the condition can be chronic and
7 last for more than a year or be persistent and last about six to
8 12 months; and

9 WHEREAS, Standard treatment consists of undergoing blood and
10 platelet transfusions and plasma exchanges and managing ITP
11 caused by some viral, bacterial and other infections; and

12 WHEREAS, A splenectomy may also be necessary to remove the
13 spleen in order to prevent platelets from being circulated and
14 potentially destroyed by antibodies; and

15 WHEREAS, Recovery from ITP varies depending on the
16 individual, and there is no cure or treatment that is guaranteed
17 to be effective; and

18 WHEREAS, Patients often have to undergo different treatments
19 and medications to determine which is most effective for their
20 condition; and

21 WHEREAS, While children are more likely to recover from ITP
22 without treatment, adults tend to recover at slower rates and
23 may require treatment for the rest of their lives; and

24 WHEREAS, Patients with ITP may need to avoid participating in
25 contact sports and other activities due to potential injuries
26 and avoid taking certain medications because of the high risk of
27 internal bleeding; and

28 WHEREAS, More than 50,000 people in the United States are
29 surviving and managing their ITP; and

30 WHEREAS, While ITP can affect anyone of any age, studies have

1 shown that women 30 to 60 years of age are more likely to have
2 ITP; and

3 WHEREAS, It is crucial to spread awareness for rare
4 autoimmune diseases such as ITP to encourage research studies to
5 be conducted, discovery of more effective treatments and
6 potential cures and to support those who are impacted by the
7 conditions; therefore be it

8 RESOLVED, That the House of Representatives recognize the
9 month of September 2026 as "ITP Awareness Month" in
10 Pennsylvania.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0494 PN3306	Prepared By:	Patrick O'Rourke (717) 787-4296
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Young, Regina		
Date:	5/28/2026		

A. Brief Concept

Designates June 15, 2026 as "Elora Joyce Khan Pediatric Brain Cancer Awareness Day."

C. Analysis of the Bill

Elora Joyce Khan, was a young Pennsylvanian who battled Diffuse Intrinsic Pontine Glioma (DIPG), a rare and aggressive brainstem cancer with no cure and few treatment options. The disease causes severe neurological symptoms and is typically diagnosed through imaging and biopsy. About 5,000 children are diagnosed annually and that brain cancer is the leading cause of cancer-related death among children, despite limited research funding and awareness. While there is no cure for DIPG, there are forms of treatment that can extend a child's life.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 494 Session of
2026

INTRODUCED BY YOUNG, CONKLIN, HILL-EVANS, CEPEDA-FREYTIZ,
WAXMAN, GUZMAN, HOHENSTEIN, MADSEN, SANCHEZ, PASHINSKI,
BELLMON, CURRY AND BRIGGS, APRIL 27, 2026

REFERRED TO COMMITTEE ON HEALTH, APRIL 29, 2026

A RESOLUTION

1 Designating June 15, 2026, as "Elora Joyce Khan Pediatric Brain
2 Cancer Awareness Day" in Pennsylvania to promote education,
3 compassion, advocacy and research related to pediatric brain
4 cancer.

5 WHEREAS, An estimated 5,000 children are diagnosed with a
6 brain tumor every year; and

7 WHEREAS, Pediatric brain cancer remains the leading cause of
8 cancer-related death among children, yet continues to receive
9 disproportionately low levels of research funding and public
10 awareness; and

11 WHEREAS, Elora Joyce Khan was a beloved daughter and young
12 Pennsylvanian whose life, though far too brief, was marked by
13 extraordinary courage, faith, compassion and joy; and

14 WHEREAS, Elora was diagnosed with Diffuse Intrinsic Pontine
15 Glioma (DIPG), a rare and aggressive pediatric brain cancer with
16 limited treatment options and devastating outcomes for children
17 and their families; and

18 WHEREAS, DIPG is a cancerous tumor that grows in a child's

1 brainstem and can also affect the central nervous system, brain
2 and spinal cord; and

3 WHEREAS, The disease can lead to headaches, vision problems,
4 challenges with muscle coordination, weakness in the limbs and
5 difficulties with eating; and

6 WHEREAS, A biopsy and magnetic resonance imaging are
7 currently used to diagnose DIPG in patients; and

8 WHEREAS, While there is no cure for DIPG, there are forms of
9 treatment that can extend a child's life; and

10 WHEREAS, Throughout her seven months of illness, Elora
11 inspired all who knew her through her strength, hope and
12 unwavering spirit; and

13 WHEREAS, Elora's legacy continues through the Elora J. Khan
14 Foundation, established in her memory to advance pediatric brain
15 tumor research, provide critical support to families facing
16 childhood cancer and create moments of hope, healing and
17 compassion locally and globally; and

18 WHEREAS, Increasing awareness, advocacy and investment in
19 pediatric cancer research and family support are essential to
20 improving outcomes and easing the burdens faced by children and
21 their loved ones; therefore be it

22 RESOLVED, That the House of Representatives designate June
23 15, 2026, as "Elora Joyce Khan Pediatric Brain Cancer Awareness
24 Day" in Pennsylvania to promote education, compassion, advocacy
25 and research related to pediatric brain cancer; and be it
26 further

27 RESOLVED, That the House of Representatives honor the life
28 and legacy of Elora Joyce Khan and recognize the meaningful
29 impact of the Elora J. Khan Foundation in supporting children
30 and families affected by pediatric cancer; and be it further

1 RESOLVED, That a copy of this resolution be transmitted to
2 the family of Elora Joyce Khan as an expression of respect,
3 remembrance and this Commonwealth's commitment to supporting
4 children battling pediatric cancer.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0502 PN3311	Prepared By:	Patrick O'Rourke (717) 787-4296,6711
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Malagari, Steve		
Date:	5/28/2026		

A. Brief Concept

Recognizes September 2026 as "Thyroid Cancer Awareness Month."

C. Analysis of the Bill

The thyroid gland, located in the front of the neck, produces hormones that regulate metabolism. Thyroid disorders include:

- Hypothyroidism, where the gland underproduces hormones, leading to symptoms like fatigue and weight gain. It's typically treated with synthetic thyroid hormones.
- Hyperthyroidism, where the gland overproduces hormones, causing weight loss, rapid heartbeat, and anxiety. Treatments include medications, radioactive iodine, or surgery.

Thyroid cancer can present with a neck lump, voice changes, or difficulty swallowing. Risk factors include high estrogen levels, radiation exposure, and certain genetic conditions. Papillary thyroid cancer is the most common type, making up 80–85% of cases. In 2025, about 44,020 new cases are expected, with women making up the majority. The average age of diagnosis is 51. Thyroid cancer is often curable with treatment, and has a five-year survival rate of 98.4%. Only 0.4% of cases are fatal.

Overall, about 20 million Americans have a thyroid disorder, with women being five to eight times more likely than men to be affected.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2025-2026 Legislative Session

- [HR264, PN1962](#) (Malagari)
 - Recognized September 2025 as "Thyroid Cancer Awareness Month."
 - Adopted 6/30/25 (200-3).

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 502 Session of
2026

INTRODUCED BY MALAGARI, GUZMAN, HOHENSTEIN, CONKLIN, McNEILL,
HILL-EVANS, KAZEEM, SANCHEZ, FREEMAN, GUENST, BENNINGHOFF,
DOUGHERTY, MADDEN, CEPEDA-FREYTIZ, PASHINSKI, RIVERA,
GALLAGHER, NEILSON AND CURRY, APRIL 29, 2026

REFERRED TO COMMITTEE ON HEALTH, APRIL 29, 2026

A RESOLUTION

1 Recognizing the month of September 2026 as "Thyroid Cancer
2 Awareness Month" in Pennsylvania.

3 WHEREAS, The thyroid gland is a butterfly-shaped gland
4 located in the front of the neck that produces the thyroid
5 hormones, which are involved in regulating an individual's
6 metabolism; and

7 WHEREAS, There are a number of conditions that an individual
8 can suffer from if the individual's thyroid is not functioning
9 properly; and

10 WHEREAS, One thyroid condition, hypothyroidism, occurs when
11 the thyroid gland does not produce enough of a thyroid hormone;
12 and

13 WHEREAS, Hypothyroidism can cause a variety of symptoms,
14 including fatigue and unexplained weight gain; and

15 WHEREAS, Treatment of hypothyroidism typically includes the
16 prescription of a synthetic thyroid hormone to restore adequate
17 hormone levels and reduce or eliminate symptoms; and

1 WHEREAS, Another thyroid condition, hyperthyroidism, occurs
2 when the thyroid gland produces too much of a thyroid hormone;
3 and

4 WHEREAS, Symptoms of hyperthyroidism include unintentional
5 weight loss, rapid or irregular heartbeat and increased
6 nervousness, anxiety and irritability; and

7 WHEREAS, A number of medications may be prescribed to treat
8 hyperthyroidism, including radioactive iodine, anti-thyroid
9 medications, beta blockers and even surgery in rare cases; and

10 WHEREAS, Additionally, thyroid cancer is a condition that can
11 be accompanied by symptoms such as a lump in the neck, changes
12 to an individual's voice, difficulty swallowing, pain in the
13 neck and throat and swollen lymph nodes; and

14 WHEREAS, Factors that can increase the risk of thyroid cancer
15 include having higher levels of estrogen, exposure to high
16 levels of radiation and inherited genetic syndromes, such as
17 familial medullary thyroid cancer, multiple endocrine neoplasia,
18 and papillary thyroid cancer; and

19 WHEREAS, Papillary thyroid cancer is the most common type of
20 thyroid cancer with it accounting for 80% to 85% of all thyroid
21 cancer cases; and

22 WHEREAS, The American Cancer Society estimated that there
23 were 44,020 new cases of diagnosed thyroid cancer in 2025, with
24 31,350 of those diagnosed being women and 12,670 of those
25 diagnosed being men; and

26 WHEREAS, Thyroid cancer can be diagnosed at any age but the
27 average age is 51 years old; and

28 WHEREAS, Thyroid cancer can typically be cured with treatment
29 or surgery to remove all or most of the thyroid gland; and

30 WHEREAS, Due to how well thyroid cancers respond to

1 treatment, about 0.4% of thyroid cancer cases are fatal and the
2 five-year relative survival rate is 98.4%; and

3 WHEREAS, Approximately 20 million Americans have some form of
4 thyroid disease, with women being five to eight times more
5 likely than men to have thyroid issues; and

6 WHEREAS, It is important to spread awareness of thyroid
7 conditions, cancers and treatments in order to improve diagnosis
8 and treatment outcomes for affected individuals; therefore be it

9 RESOLVED, That the House of Representatives recognize the
10 month of September 2026 as "Thyroid Cancer Awareness Month" in
11 Pennsylvania.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0514 PN3361	Prepared By:	Patrick O'Rourke (717) 705-1875
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Diamond, Russell		
Date:	5/28/2026		

A. Brief Concept

Designates October 13th, 2026, as "Metastatic Breast Cancer Awareness Day."

C. Analysis of the Bill

Metastatic breast cancer occurs when breast cancer spreads to other parts of the body, including the bones, lungs, liver and brain has an average life expectancy of 24-36 months. Regardless of early detection, approximately 30% of stage 0 to III breast cancers will return as stage IV. An estimated 42,250 Americans will die from breast cancer in 2025, equal to approximately 115 individuals per day, with 98% due to metastatic breast cancer.

In the United States, less than 5% of breast cancer research dollars are used for patients that already have metastasized breast cancer. The national organization, METAvivor Research and Support, aims to increase that figure to 30% by funding critical stage IV metastatic breast cancer research and educating the public about metastatic breast cancer. On October 13 of every year, there is a global "LightUpMBC campaign to illuminate 115 landmarks in the metastatic colors of teal, pink and green throughout the world, which brings awareness to the disease and honors the daily number of 115 lives lost to metastatic breast cancer. The day will culminate in a virtual broadcast, #LightUpMBC Live, to commemorate landmarks lighting around the country, share inspiring stories by the metastatic breast cancer community and raise research funds.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes).

2023-24 Legislative Session

- [HR 164, PN 1754](#) (Diamond)
 - Designating October 13, 2023, as "Metastatic Breast Cancer Awareness Day."
 - Adopted 10/3/2023 (202-1).
- [SR 175, PN 1128](#) (Gebhard)
 - Designating October 13, 2023, as "Metastatic Breast Cancer Awareness Day."
 - Not reported out of committee.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 514 Session of
2026

INTRODUCED BY DIAMOND, PICKETT, STAMBAUGH, McNEILL, HOWARD,
KHAN, VENKAT, CUTLER, HANBIDGE, WALLEN, RIVERA, NEILSON,
BENNINGHOFF, GILLEN AND ANDERSON, MAY 4, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 6, 2026

A RESOLUTION

1 Designating October 13, 2026, as "Metastatic Breast Cancer
2 Awareness Day" in Pennsylvania.

3 WHEREAS, Breast cancer is the most common type of cancer
4 among women in the world, and second leading cause of cancer
5 death among women in the United States; and

6 WHEREAS, More than one in eight women and one in 833 men in
7 the United States will be diagnosed with breast cancer in their
8 lifetimes; and

9 WHEREAS, In 2026, an estimated 321,910 Americans will be
10 diagnosed with new cases of invasive breast cancer; and

11 WHEREAS, Metastatic breast cancer occurs when breast cancer
12 spreads to other parts of the body, including the bones, lungs,
13 liver and brain and has an average life expectancy of 24 to 36
14 months; and

15 WHEREAS, Regardless of early detection, approximately 30% of
16 stage 0 to III breast cancers will return as stage IV; and

17 WHEREAS, An estimated 42,670 Americans will die from breast

1 cancer in 2026, equal to approximately 117 individuals per day;
2 and

3 WHEREAS, The national organization, METAvivor Research and
4 Support, funds critical stage IV metastatic breast cancer
5 research, educates the public about metastatic breast cancer and
6 lack of funding for stage IV treatment; and

7 WHEREAS, METAvivor Research and Support aims to dramatically
8 increase the current percentage of United States breast cancer
9 research dollars from under 5% to 30% for the already
10 metastasized patient; and

11 WHEREAS, The national hashtags for this initiative on social
12 media fall under #METAvivor and #LightUpMBC; and

13 WHEREAS, On October 13, more than 270 landmarks across the
14 United States and around the world will light up in the colors
15 of teal, green and pink in a show of solidarity with the
16 metastatic breast cancer community as part of the #LightUpMBC
17 Campaign to benefit METAvivor; and

18 WHEREAS, The day will culminate in a virtual broadcast,
19 #LightUpMBC Live, to commemorate landmarks lighting around the
20 country, share inspiring stories by the metastatic breast cancer
21 community and raise research funds; and

22 WHEREAS, The pink ribbon is well-known for representing the
23 fight against early stage breast cancer and is not inclusive of
24 stage IV; therefore be it

25 RESOLVED, That the House of Representatives designate
26 October 13, 2026, as "Metastatic Breast Cancer Awareness Day" in
27 Pennsylvania; and be it further

28 RESOLVED, That the House of Representatives recognize the
29 METAvivor #LightUpMBC national campaign.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0518 PN3362	Prepared By:	Patrick O'Rourke (717) 705-1875
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Diamond, Russell		
Date:	5/29/2026		

A. Brief Concept

House Resolution 74 recognizes November 2026 as "National Epilepsy Awareness Month."

C. Analysis of the Bill

Epilepsy, a neurological disorder characterized by recurring seizures, affects 3.4 million Americans of all ages and is the fourth most common neurological disorder in the United States. Approximately 1 in 26 people will develop epilepsy in their lifetime and approximately 150,000 new cases of epilepsy are diagnosed each year, most often in young children and senior citizens.

The Epilepsy Association of Western and Central Pennsylvania and the Epilepsy Foundation of Eastern Pennsylvania have been serving the needs of Pennsylvanians who live with epilepsy and seizures since 1972 and leads the fight to stop seizures, find a cure and overcome the challenges created by epilepsy.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2023-24 Legislative Session

- [HR 74, PN 586](#) (Diamond)
 - Recognizes November 2025 as "National Epilepsy Awareness Month."
 - Laid on the table (Pursuant to House Rule 71), June 4, 2025.

2023-24 Legislative Session

- [HR 479, PN 3345](#) (Hogan)
 - Recognizes November 2024 as "National Epilepsy Awareness Month."
 - Did not receive a vote on the floor.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 518 Session of
2026

INTRODUCED BY DIAMOND, HOGAN, HARKINS, STAATS, PICKETT, McNEILL,
JAMES, VENKAT, ROWE, HANBIDGE, WALLEN, RIVERA, NEILSON,
OLSOMMER, BENNINGHOFF, MERSKI, BOROWSKI AND ANDERSON,
MAY 5, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 6, 2026

A RESOLUTION

1 Recognizing the month of November 2026 as "National Epilepsy
2 Awareness Month" in Pennsylvania.

3 WHEREAS, Epilepsy is a neurological condition sometimes
4 referred to as a seizure disorder and is characterized by
5 recurring seizures; and

6 WHEREAS, A seizure is usually defined as a sudden alteration
7 of behavior due to a temporary change in electrical functioning
8 of the brain; and

9 WHEREAS, Normally, the brain continuously generates tiny
10 electrical impulses in an orderly pattern and these impulses
11 travel along neurons and throughout the whole body via chemical
12 messengers called neurotransmitters; and

13 WHEREAS, In epilepsy, the brain's electrical rhythms have a
14 tendency to become imbalanced, resulting in recurrent seizures;
15 and

16 WHEREAS, In patients with seizures, the normal electrical
17 pattern is disrupted by sudden and synchronized bursts of

1 electrical energy that may briefly affect their consciousness,
2 movements or sensations; and

3 WHEREAS, As the fourth most common neurological disorder in
4 the United States, following migraine, stroke and Alzheimer's
5 disease, epilepsy affects 3.4 million Americans of all ages; and

6 WHEREAS, Approximately 150,000 new cases of epilepsy are
7 diagnosed each year, most often in young children and senior
8 citizens; and

9 WHEREAS, One in 26 people will develop epilepsy in his or her
10 lifetime; and

11 WHEREAS, Up to 50,000 Americans die each year from seizures
12 and related causes, including sudden unexplained death in
13 epilepsy; and

14 WHEREAS, The Epilepsy Association of Western and Central
15 Pennsylvania and the Epilepsy Foundation of Eastern Pennsylvania
16 lead the fight to stop seizures, find a cure and overcome the
17 challenges created by epilepsy; and

18 WHEREAS, The Epilepsy Association of Western and Central
19 Pennsylvania and the Epilepsy Foundation of Eastern Pennsylvania
20 are dedicated to ensuring that all people with seizures and
21 epilepsy are able to participate in all of life's experiences;
22 and

23 WHEREAS, The Epilepsy Association of Western and Central
24 Pennsylvania and the Epilepsy Foundation of Eastern Pennsylvania
25 have been serving the needs of Pennsylvanians who live with
26 seizures since 1972; and

27 WHEREAS, Misinformation and misperceptions regarding epilepsy
28 have a long history and are still prevalent throughout society
29 today; and

30 WHEREAS, Epilepsy education and awareness programs seek to

1 combat stigma in the hope of improving the quality of life for
2 people with epilepsy; therefore be it

3 RESOLVED, That the House of Representatives recognize the
4 month of November 2026 as "National Epilepsy Awareness Month" in
5 Pennsylvania.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0529 PN3419	Prepared By:	Patrick O'Rourke (717) 787-4296,6711
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Rapp, Kathy		
Date:	5/29/2026		

A. Brief Concept

Designates the week of September 20 through 27, 2026 as "Idiopathic Pulmonary Fibrosis Research and Awareness Week."

C. Analysis of the Bill

Idiopathic pulmonary fibrosis is marked by progressive scarring of the lungs, causing an irreversible loss of the lung tissue's ability to transport oxygen. It is a generally fatal condition, often causing death within three to five years. There is no known cause and it often get misdiagnosed or underdiagnosed. AN estimated 132,000 to 200,000 Americans have the condition. Each year approximately 40,000 individuals die from the condition and more than 48,000 new cases are diagnosed.

In Pennsylvania, approximately 7,000 residents are presently diagnosed with idiopathic pulmonary fibrosis. Relatedly, the Commonwealth is a leader in research and treatment of idiopathic pulmonary fibrosis, with more than 15% of all lung transplants in the United States performed in Pennsylvania hospitals. Organizations like the Wescoe Foundation for Pulmonary Fibrosis and the Pennsylvania Idiopathic Pulmonary Fibrosis Support Network play a crucial role in raising awareness and providing support and education for patients, families and health care providers throughout the state.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2025-2026 Legislative Session

- [HR249, PN1836](#) (Rapp)
 - Designated September 21 through 28, 2025, as "Idiopathic Pulmonary Fibrosis Research and Awareness Week."
 - Laid on the table (Pursuant to House Rule 71), July 9, 2025.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 529 Session of
2026

INTRODUCED BY RAPP, VENKAT, KAUFFMAN, PICKETT, RIVERA AND
GALLAGHER, MAY 14, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 20, 2026

A RESOLUTION

1 Designating the week of September 20 through 27, 2026, as
2 "Idiopathic Pulmonary Fibrosis Research and Awareness Week"
3 in Pennsylvania to increase awareness and understanding of
4 idiopathic pulmonary fibrosis to support improved diagnosis
5 and treatment.

6 WHEREAS, Idiopathic pulmonary fibrosis is a debilitating and
7 generally fatal disease marked by progressive scarring of the
8 lungs, causing an irreversible loss of the lung tissue's ability
9 to transport oxygen; and

10 WHEREAS, Idiopathic pulmonary fibrosis progresses quickly,
11 often causing disability or death within three to five years;
12 and

13 WHEREAS, Idiopathic pulmonary fibrosis is the most common
14 form of interstitial lung disease; and

15 WHEREAS, There is no proven cause of idiopathic pulmonary
16 fibrosis, and it is often misdiagnosed or underdiagnosed; and

17 WHEREAS, Idiopathic pulmonary fibrosis is five times more
18 common than cystic fibrosis and Lou Gehrig's disease, yet the
19 disease remains virtually unknown and receives a fraction of the

1 research funding; and

2 WHEREAS, It is estimated that idiopathic pulmonary fibrosis
3 affects between 132,000 to 200,000 individuals in the United
4 States and more than 48,000 new cases are diagnosed each year;
5 and

6 WHEREAS, Approximately 40,000 people die each year due to
7 idiopathic pulmonary fibrosis, which is similar to the number of
8 deaths that occur due to breast cancer; and

9 WHEREAS, Approximately 7,000 Pennsylvanians suffer from
10 idiopathic pulmonary fibrosis; and

11 WHEREAS, This Commonwealth has become a leader in the
12 research and treatment of idiopathic pulmonary fibrosis, with
13 more than 15% of all lung transplants in the United States
14 performed in Pennsylvania hospitals; and

15 WHEREAS, Organizations like the Wescoe Foundation for
16 Pulmonary Fibrosis play a crucial role in raising awareness and
17 providing support and education for patients, families and
18 health care providers throughout this Commonwealth; and

19 WHEREAS, Increased research, awareness and detection of
20 idiopathic pulmonary fibrosis is needed; therefore be it

21 RESOLVED, That the House of Representatives designate the
22 week of September 20 through 27, 2026, as "Idiopathic Pulmonary
23 Fibrosis Research and Awareness Week" in Pennsylvania to
24 increase awareness and understanding of idiopathic pulmonary
25 fibrosis to support improved diagnosis and treatment.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0531 PN3421	Prepared By:	Patrick O'Rourke (717) 787-4296
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Delozier, Sheryl		
Date:	5/29/2026		

A. Brief Concept

Designates June 2026 as "Scoliosis Awareness Month."

C. Analysis of the Bill

Scoliosis is a spinal condition that causes a sideways "S" or "C" curvature and affects millions of Americans, often beginning in adolescence. Early detection through screenings and regular checkups is key to preventing severe deformities and reducing the need for surgery. National organizations and local advocates across Pennsylvania play an important role in raising awareness, supporting patients and families, and expanding access to care and resources.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 531 Session of
2026

INTRODUCED BY DELOZIER, RAPP, GALLAGHER, McNEILL, NEILSON, PUGH,
RIVERA, STEHR AND VENKAT, MAY 15, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 20, 2026

A RESOLUTION

1 Designating the month of June 2026 as "Scoliosis Awareness
2 Month" in Pennsylvania.

3 WHEREAS, Scoliosis is a condition characterized by an
4 abnormal side to side curvature of the spine, often appearing as
5 an "S" or "C" shape rather than a straight line; and

6 WHEREAS, An estimated 6 million to 9 million people in the
7 United States are affected by scoliosis, with idiopathic
8 scoliosis, the most common form, typically developing in
9 preteens and teenagers; and

10 WHEREAS, Early detection through school screenings and
11 regular physical examinations is critical to preventing severe
12 spinal deformity and reducing the need for invasive surgical
13 procedures; and

14 WHEREAS, Organizations such as the Scoliosis Research Society
15 and the National Scoliosis Foundation work tirelessly to unite
16 patients, families and clinicians in a collaborative effort to
17 advocate for enhanced patient care, awareness and protection;
18 and

1 WHEREAS, Young advocates in this Commonwealth, like Ella from
2 the 88th Legislative District, are leading initiatives to
3 increase public understanding, provide peer support and partner
4 with medical providers to expand access to resources across this
5 Commonwealth; therefore be it

6 RESOLVED, That the House of Representatives designate the
7 month of June 2026 as "Scoliosis Awareness Month" in
8 Pennsylvania; and be it further

9 RESOLVED, That the House of Representatives urge all
10 Pennsylvanians to learn more about this condition and support
11 early screening efforts to improve the quality of life for
12 individuals affected by scoliosis.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0535 PN3441	Prepared By:	Patrick O'Rourke (717) 705-1875
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Rapp, Kathy		
Date:	5/29/2026		

A. Brief Concept

Designates the week of September 20 through 26, 2026, as "Surgical Technologist Week."

C. Analysis of the Bill

The resolution recognizes the essential role that surgical technologists play in the health care system of the Commonwealth. These professionals are fundamental members of the surgical team and contribute to patient safety, quality of medical care, and operating room efficiency.

The resolution highlights the following:

- Surgical technologists, also known as "scrubs," work closely with surgeons, nurses, anesthesiologists, and other health professionals in a variety of roles before, during, and after surgical procedures.
- All major hospitals and ambulatory surgical centers in Pennsylvania employ surgical technologists to support operations and ensure safe and effective medical care.
- Due to the aging population and technological advances (such as the use of lasers and fiber optics), demand for trained surgical technologists is expected to grow at a rate higher than the average for all occupations.
- Currently, 18 accredited programs in the Commonwealth educate and graduate qualified professionals in surgical technology each year.
- The Association of Surgical Technologists designates one week each September as a national recognition week to promote and raise awareness of the profession.
- This resolution serves as an official recognition by the House of Representatives of the important contributions surgical technologists make to the public health of Pennsylvania residents.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2025-26 Legislative Session:

- [HR255 PN1888](#) (Rapp)
 - A Resolution designating the week of September 21 through 27, 2025, as "Surgical Technologist Week" in Pennsylvania.
 - Laid on the table (Pursuant to House Rule 71), July 15, 2025.

2023-24 Legislative Session:

- [HR523 PN3612](#) (Rapp)
 - A Resolution designating the week of September 15 through 21, 2024, as "Surgical Technologist Week" in Pennsylvania.
 - Reported as committed 10/02/24.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 535 Session of
2026

INTRODUCED BY RAPP, VENKAT, KAUFFMAN AND RIVERA, MAY 26, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 27, 2026

A RESOLUTION

1 Designating the week of September 20 through 26, 2026, as
2 "Surgical Technologist Week" in Pennsylvania.

3 WHEREAS, Surgical technologists play a vital role in the care
4 and health of surgical patients in this Commonwealth; and

5 WHEREAS, Surgical technologists, also called scrubs, play an
6 integral role in the surgical team, serving in many capacities
7 alongside surgeons, nurses, anesthesia providers and other
8 health care personnel; and

9 WHEREAS, All major hospitals and ambulatory surgical centers
10 in this Commonwealth employ surgical technologists to work with
11 surgeons in the operating room to provide quality patient care;
12 and

13 WHEREAS, As a large percentage of the general population
14 approaches retirement age and as technological advances such as
15 fiber optics and laser technology permit new surgical
16 procedures, employment of surgical technologists who are
17 educated in these technologies is expected to grow faster than
18 average for all occupations; and

1 WHEREAS, In this Commonwealth, 18 programs in surgical
2 technology graduate quality students; and

3 WHEREAS, Each year the Association of Surgical Technologists
4 designates a week in September as "National Surgical
5 Technologists Week" to celebrate and promote the profession; and

6 WHEREAS, It is fitting that these medical professionals
7 receive recognition for their contributions to the care and
8 health of the residents of this Commonwealth; therefore be it

9 RESOLVED, That the House of Representatives designate the
10 week of September 20 through 26, 2026, as "Surgical Technologist
11 Week" in Pennsylvania.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0538 PN3444	Prepared By:	Patrick O'Rourke (717) 787-4296,6711
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Matzie, Robert		
Date:	5/29/2026		

A. Brief Concept

Designates November 2026 as "Pancreatic Cancer Awareness Month."

C. Analysis of the Bill

The pancreas is a gland behind the stomach which produces fluids for digestion and hormones to control blood sugar levels. Pancreatic cancer is the third leading cause of cancer-related deaths for adults in the United States.

Pancreatic cancer is very difficult to detect and treat. It usually has no symptoms in the early stages and spreads through the body very quickly. Some symptoms of pancreatic cancer are jaundice, weight loss, abdominal pain, nausea, and vomiting. Risk factors include age, genetics, smoking, obesity, and diabetes.

Organizations such as the Pancreatic Cancer Action Network and the National Pancreas Foundation support patients with pancreatic cancer. They focus on public policy, research funding, public awareness, and patient services. "Pancreatic Cancer Awareness Month" is celebrated each November to strengthen awareness efforts about pancreatic cancer.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2025-26 Legislative Session

- HR305 PN2064 (Matzie)
 - A Resolution designating the month of November 2023 as "Pancreatic Cancer Awareness Month" in Pennsylvania.
 - Adopted 11/17/2025 (200-2)

2023-24 Legislative Session

- HR227 PN2064 (Matzie)
 - A Resolution designating the month of November 2023 as "Pancreatic Cancer Awareness Month" in Pennsylvania.
 - Adopted 11/15/2023 (202-1)

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 538 Session of
2026

INTRODUCED BY MATZIE, DEASY, McANDREW, VENKAT, DONAHUE, CONKLIN,
HARKINS, HILL-EVANS, NEILSON, FREEMAN, GUZMAN, DELLOSO,
McNEILL, SANCHEZ, RIVERA, HADDOCK, CEPEDA-FREYTIZ, GALLAGHER,
PASHINSKI, MALAGARI, D. WILLIAMS, MADDEN, HOHENSTEIN, CIRESI,
CURRY, JAMES, PICKETT, GAYDOS, CUTLER AND CAUSER,
MAY 26, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 27, 2026

A RESOLUTION

1 Designating the month of November 2026 as "Pancreatic Cancer
2 Awareness Month" in Pennsylvania.

3 WHEREAS, The pancreas is a thin, pear-shaped gland behind the
4 stomach that plays an important role in the digestive system by
5 producing fluids to help break down food and hormones to control
6 blood sugar levels; and

7 WHEREAS, There are typically no symptoms during the early
8 stages of pancreatic cancer, and it spreads quickly throughout
9 the body, making it difficult to detect and harder to treat in
10 later stages; and

11 WHEREAS, Symptoms that could indicate pancreatic cancer
12 include upper abdominal pain, weight loss, jaundice, severe
13 itching, digestive problems, nausea and vomiting; and

14 WHEREAS, The exact cause of pancreatic cancer is yet to be
15 determined; and

16 WHEREAS, Risk factors, including genetics, age, smoking,

1 obesity and long-standing diabetes, may contribute to the
2 development of pancreatic cancer; and

3 WHEREAS, Pancreatic cancer is the third-leading cause of
4 cancer-related deaths in men and women in the United States each
5 year; and

6 WHEREAS, Organizations such as the Pancreatic Cancer Action
7 Network and the National Pancreas Foundation are committed to
8 helping and empowering patients suffering from pancreatic
9 cancer, focusing efforts on public policy, research funding,
10 patient services and public awareness and developing effective
11 treatments and a cure for pancreatic cancer; and

12 WHEREAS, "Pancreatic Cancer Awareness Month" is celebrated
13 each November to highlight awareness efforts and strengthen the
14 voices speaking out about pancreatic cancer; and

15 WHEREAS, The good health and well-being of the residents of
16 this Commonwealth are enhanced as a direct result of increased
17 awareness about pancreatic cancer and research regarding early
18 detection, causes and effective treatments; therefore be it

19 RESOLVED, That the House of Representatives designate the
20 month of November 2026 as "Pancreatic Cancer Awareness Month" in
21 Pennsylvania; and be it further

22 RESOLVED, That the House of Representatives strongly support
23 educational activities and programs designed to strengthen
24 awareness and support those living with pancreatic cancer.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0541 PN3457	Prepared By:	Patrick O'Rourke (717) 787-4296
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Brown, Marla		
Date:	5/29/2026		

A. Brief Concept

Recognizes June 2026 as "Aphasia Awareness Month."

C. Analysis of the Bill

Aphasia is a language disorder caused primarily by stroke, as well as brain injuries and neurological diseases, affecting a person's ability to speak, understand, read, or write. An estimated 2 to 4 million Americans live with aphasia, with about 800,000 new cases each year, impacting not only individuals but also their families and communities. The condition varies depending on the location of brain damage, leading to different patterns of language impairment. Because aphasia often goes unrecognized, greater public awareness and stronger support for patients, caregivers, and professionals are essential to improving diagnosis, treatment, and overall care.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 541 Session of
2026

INTRODUCED BY M. BROWN, KINKEAD, VENKAT, WALLEN, KRAJEWSKI,
CURRY AND GALLAGHER, MAY 27, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 28, 2026

A RESOLUTION

1 Recognizing the month of June 2026 as "Aphasia Awareness Month"
2 in Pennsylvania to increase awareness and understanding of
3 aphasia to support improved diagnosis and treatment.

4 WHEREAS, Aphasia is a language disorder caused by stroke,
5 brain injury or neurological disease; and

6 WHEREAS, Aphasia can affect an individual's ability to speak,
7 understand language, read or write; and

8 WHEREAS, In the United States, there are an estimated 2
9 million to 4 million people who are living with aphasia, which
10 affects not only those individuals, but also the individual's
11 spouse, family members, friends and community; and

12 WHEREAS, According to the National Aphasia Association, an
13 estimated 800,000 Americans are diagnosed with aphasia every
14 year; and

15 WHEREAS, Approximately 85% of aphasia is caused due to
16 strokes and other causes, which include traumatic brain
17 injuries, brain tumors, degenerative disease and metabolic
18 changes; and

1 WHEREAS, After over a century of studying aphasia, it has
2 become evident that specific components of language may be more
3 dramatically damaged in some individuals; and

4 WHEREAS, Different types or patterns of aphasia correspond to
5 the location of the brain injury in individual cases; and

6 WHEREAS, Individuals with aphasia often go unrecognized, and
7 it is vital to support these individuals, their families and
8 professionals who help them; and

9 WHEREAS, It is imperative that there be greater public
10 awareness of this health issue, and more must be done to
11 increase activity at the Federal, State and local levels;
12 therefore be it

13 RESOLVED, That the House of Representatives recognize the
14 month of June 2026 as "Aphasia Awareness Month" in Pennsylvania
15 to increase awareness and understanding of aphasia to support
16 improved diagnosis and treatment.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HR0542 PN3458	Prepared By:	Patrick O'Rourke (717) 705-1875
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Rapp, Kathy		
Date:	5/29/2026		

A. Brief Concept

Recognizes October 24, 2026, as "World Polio Day" in Pennsylvania.

C. Analysis of the Bill

The resolution highlights the role of Rotary International as a global network of individuals promoting change through humanitarian action and their role in eradicating polio.

The following facts are emphasized:

- In 1985, Rotary launched the PolioPlus program, and in 1988 helped establish the Global Polio Eradication Initiative, in partnership with the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), UNICEF, the Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance.
- Since 1988, polio cases have decreased by 99.9%, and the world is close to eradicating the disease.
- Currently, Rotary seeks to raise \$50 million per year for three years, with each dollar matched by two additional dollars from the Gates Foundation, generating up to \$450 million in total.
- Rotary has also influenced government decisions to contribute more than \$11 billion to the global effort.
- There are over 1.4 million Rotary members in more than 46,000 clubs worldwide that develop community projects focused on poverty, disease, hunger, literacy, and the environment.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

2025-26 Legislative Session

- [HR251 PN1839](#) (Rapp)
 - A Resolution recognizing October 24, 2023, as "World Polio Day."
 - Laid on the table 7/9/2025.

2023-24 Legislative Session

- [HR244 PN2151](#) (Rapp)
 - A Resolution recognizing October 24, 2023, as "World Polio Day."
 - Laid on the table 3/20/2024.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 542 Session of 2026

INTRODUCED BY RAPP, VENKAT, PICKETT, RIVERA, VITALI, COOPER,
GALLAGHER, CIRESI AND CURRY, MAY 27, 2026

REFERRED TO COMMITTEE ON HEALTH, MAY 28, 2026

A RESOLUTION

1 Recognizing October 24, 2026, as "World Polio Day" in
2 Pennsylvania.

3 WHEREAS, Rotary is a global network of neighbors, friends,
4 leaders and problem-solvers who unite and take action to create
5 lasting change in communities across the world; and

6 WHEREAS, The Rotary motto, "Service Above Self," inspires
7 members to provide humanitarian service, follow high ethical
8 standards and promote goodwill and peace in the world; and

9 WHEREAS, In 1985, Rotary launched PolioPlus and in 1988
10 helped establish the Global Polio Eradication Initiative, which
11 today includes the World Health Organization, the Centers for
12 Disease Control and Prevention, UNICEF, the Bill & Melinda Gates
13 Foundation and Gavi, the Vaccine Alliance, to immunize the
14 children of the world against polio; and

15 WHEREAS, Polio cases have dropped by 99.9% since 1988, and
16 the world stands on the threshold of eradicating the disease;
17 and

18 WHEREAS, To date Rotary has contributed more than \$2.9

1 billion and countless volunteer hours to protecting more than 3
2 billion children in 122 countries; and

3 WHEREAS, Rotary is working to raise an additional \$50 million
4 per year over three years that would be leveraged for maximum
5 impact with every dollar to be matched with two additional
6 dollars from the Gates Foundation, which would amount to \$450
7 million total; and

8 WHEREAS, These efforts are providing much-needed operational
9 support, medical staff, laboratory equipment and educational
10 materials for health workers and parents; and

11 WHEREAS, In addition, Rotary has played a major role in
12 decisions by donor governments to contribute more than \$11
13 billion to the effort; and

14 WHEREAS, There are more than 1.4 million Rotary members in
15 more than 46,000 clubs throughout the world that sponsor service
16 projects to address such critical issues as poverty, disease,
17 hunger, illiteracy and the environment in their local
18 communities and abroad; therefore be it

19 RESOLVED, That the House of Representatives recognize October
20 24, 2026, as "World Polio Day" in Pennsylvania; and be it
21 further

22 RESOLVED, That the House of Representatives encourage all
23 citizens to join Rotary International in the fight for a polio-
24 free world.